ATE476978T1 - Verbesserung der geistigen fähigkeiten durch die steigerung der insulin-empfindlichkeit des gehirns - Google Patents

Verbesserung der geistigen fähigkeiten durch die steigerung der insulin-empfindlichkeit des gehirns

Info

Publication number
ATE476978T1
ATE476978T1 AT99966359T AT99966359T ATE476978T1 AT E476978 T1 ATE476978 T1 AT E476978T1 AT 99966359 T AT99966359 T AT 99966359T AT 99966359 T AT99966359 T AT 99966359T AT E476978 T1 ATE476978 T1 AT E476978T1
Authority
AT
Austria
Prior art keywords
brain
glucose utilization
nervous system
central nervous
agents
Prior art date
Application number
AT99966359T
Other languages
English (en)
Inventor
Daniel G Chain
Mike Cawthorne
Original Assignee
Mindset Biopharmaceuticals Usa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mindset Biopharmaceuticals Usa filed Critical Mindset Biopharmaceuticals Usa
Application granted granted Critical
Publication of ATE476978T1 publication Critical patent/ATE476978T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F42—AMMUNITION; BLASTING
    • F42C—AMMUNITION FUZES; ARMING OR SAFETY MEANS THEREFOR
    • F42C15/00—Arming-means in fuzes; Safety means for preventing premature detonation of fuzes or charges
    • F42C15/24—Arming-means in fuzes; Safety means for preventing premature detonation of fuzes or charges wherein the safety or arming action is effected by inertia means
    • F42C15/26—Arming-means in fuzes; Safety means for preventing premature detonation of fuzes or charges wherein the safety or arming action is effected by inertia means using centrifugal force

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT99966359T 1998-12-17 1999-12-17 Verbesserung der geistigen fähigkeiten durch die steigerung der insulin-empfindlichkeit des gehirns ATE476978T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11266998P 1998-12-17 1998-12-17
US12225899P 1999-02-24 1999-02-24
PCT/US1999/030066 WO2000035437A2 (en) 1998-12-17 1999-12-17 Improving mental performance by increasing brain insulin sensitivity

Publications (1)

Publication Number Publication Date
ATE476978T1 true ATE476978T1 (de) 2010-08-15

Family

ID=26810226

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99966359T ATE476978T1 (de) 1998-12-17 1999-12-17 Verbesserung der geistigen fähigkeiten durch die steigerung der insulin-empfindlichkeit des gehirns

Country Status (8)

Country Link
EP (1) EP1140081B1 (de)
JP (1) JP2002532416A (de)
AT (1) ATE476978T1 (de)
AU (3) AU2192000A (de)
CA (1) CA2355645A1 (de)
DE (1) DE69942672D1 (de)
IL (2) IL143768A0 (de)
WO (1) WO2000035437A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0030845D0 (en) * 2000-12-18 2001-01-31 Smithkline Beecham Plc Novel treatment
EP1454898A4 (de) 2001-12-13 2006-12-13 Ajinomoto Kk Neue phenylalaninderivate
US6716842B2 (en) 2002-04-05 2004-04-06 Warner-Lambert Company, Llc Antidiabetic agents
AU2006295007A1 (en) * 2005-09-22 2007-04-05 Smithkline Beecham (Cork) Limited Combination of rosiglitazone and donepezil for improvement of cognitive function
KR20100017460A (ko) * 2007-05-24 2010-02-16 시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이. 피피에이알 감마 작용물질로 인한 부작용의 예방에 유용한 조성물
US20100152249A1 (en) * 2008-12-11 2010-06-17 Board Of Trustees Of The Leland Stanford Junior University Compositons and method for treatment of mood and cognitive impairments
SG10201503032UA (en) 2010-06-16 2015-06-29 Sigma Tau Ind Farmaceuti Acetyl-carnitine for use in a method for increasing neurogenesis in neural tissue
JP6735224B2 (ja) 2016-01-28 2020-08-05 花王株式会社 アストロサイトのグルコース代謝活性化剤

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4540564A (en) * 1982-05-18 1985-09-10 University Of Florida Brain-specific drug delivery
US5039794A (en) * 1986-09-19 1991-08-13 Otsuka Pharmaceutical Co., Ltd. Tumor egress factor and processes for producing the same
IT1260155B (it) * 1992-08-03 1996-03-28 Fidia Spa Uso terapeutico della fosforil-l-serina-n-acil-sfingosina
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
WO1999016758A1 (en) * 1997-10-27 1999-04-08 Dr. Reddy's Research Foundation Novel heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
WO1999020614A1 (en) * 1998-05-27 1999-04-29 Dr. Reddy's Research Foundation Bicyclic compounds, process for their preparation and pharmaceutical compositions containing them
EP1051403A1 (de) * 1998-01-29 2000-11-15 Dr. Reddy's Research Foundation Alkansaüren und deren verwendung in heilmittel, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen
GB9822473D0 (en) * 1998-10-16 1998-12-09 Glaxo Group Ltd Chemical compounds
WO2000023451A1 (en) * 1998-10-21 2000-04-27 Novo Nordisk A/S New compounds, their preparation and use
JP2002527516A (ja) * 1998-10-21 2002-08-27 ノボ ノルディスク アクティーゼルスカブ 新規化合物、それらの製造及び使用
WO2000023415A1 (en) * 1998-10-21 2000-04-27 Novo Nordisk A/S New compounds, their preparation and use
AU6325699A (en) * 1998-10-21 2000-05-08 Dr. Reddy's Research Foundation New compounds, their preparation and use
EP1123269A1 (de) * 1998-10-21 2001-08-16 Novo Nordisk A/S Neuartige verbindungen, ihre herstellung und ihre verwendung
US6028088A (en) * 1998-10-30 2000-02-22 The University Of Mississippi Flavonoid derivatives
US6191154B1 (en) * 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases

Also Published As

Publication number Publication date
WO2000035437A3 (en) 2000-11-09
CA2355645A1 (en) 2000-06-22
IL143768A (en) 2008-04-13
DE69942672D1 (de) 2010-09-23
IL143768A0 (en) 2002-04-21
EP1140081A2 (de) 2001-10-10
EP1140081B1 (de) 2010-08-11
WO2000035437A2 (en) 2000-06-22
AU2005201243A1 (en) 2005-04-21
AU2009200266A1 (en) 2009-02-19
AU2192000A (en) 2000-07-03
JP2002532416A (ja) 2002-10-02

Similar Documents

Publication Publication Date Title
Tarsy et al. Physostigmine in choreiform movement disorders
DE69930739D1 (de) Transdermale verwendung von sekretin zur behandlung von autismus
DE3687501D1 (de) Verwendung von gamma-linolensaeure und verwandten verbindungen zur herstellung eines arneimittels zur behandlung von komplikationen bei diabetes mellitus.
ATE202076T1 (de) Ester der 5-aminolevulinsäure als mittel zur photosensibilisierung in der chemotherapie
DE69519099D1 (de) Aromatische aminoether als schmerzlindernde mittel
HUP0301749A2 (hu) Acilfenil-karbamid-származékok, eljárás az elżállításukra és gyógyszerkénti alkalmazásuk
RU93055137A (ru) Гетероцикло-циклические производные аминов, способ получения, промежуточные соединения, фармацевтическая композиция, способ лечения
IE41374B1 (en) A composition for treating schizophrenia
ATE476978T1 (de) Verbesserung der geistigen fähigkeiten durch die steigerung der insulin-empfindlichkeit des gehirns
SE8105561L (sv) Anvendning av pyridoxin-alfa-ketoglutarat vid profylax av hypermjolksyraemi
Mertens Long-term treatment of chronic schizophrenia patients with risperidone
FI874865A (fi) Menetelmä lääkeaineena käyttökelpoisten imidatsolidinonijohdannaisten valmistamiseksi
Boller et al. Alzheimer's disease and THA: a review of the cholinergic theory and of preliminary results
ATE162718T1 (de) Verwendung von prostacyclin-derivaten zur verhinderung oder behandlung von störungen der mikrozirkulation bei gabe von röntgen-, nmr- oder ultraschallkontrastmitteln
DE59602626D1 (de) Neuartig substituierte dtpa-derivate, deren metallkomplexe, diese komplexe enthaltende pharmazeutische mittel, deren verwendung in der diagnostik und therapie, sowie verfahren zur herstellung der komplexe und mittel
KR870007937A (ko) 2β-치환된 티오 메틸페니실린 유도체 및 그의 제조방법 및 용도
Davidoff et al. Enhancement of the mitochondrial Ca2+ uptake rate by phenethylbiguanide and other organic cations with hypoglycemic activity
Cotzias L-Dopa in Parkinson's disease
KR880009944A (ko) 피페라진 카르복실산, 그의 제조방법 및 그를 함유하는 약학적 조성물
Cahn et al. Observations on the Clinical Effects of a new Tranquillizing Agent in Psychotic Conditions
Chayasirisobhon et al. Occurrence of neuroleptic malignant syndrome in a narcoleptic patient
KR880004810A (ko) 소화성 궤양 치료제
EP0255704A3 (de) Pyridazinon-Derivate, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel
JPS59193891A (ja) リフアマイシン誘導体及びその製造方法並びに該誘導体を含有する医薬
Dawson et al. Cardiac dysrhythmia with the use of clonidine in explosive disorder

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties